Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Celgene acquiring Pharmion for $2.9B

PHRM jumped $15.84 (32%) to $65.12 on Monday after CELG said it will acquire the cancer and hematology company for $72 per share, consisting of $25 in cash

Read the full 285 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE